These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 31296289

  • 1. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP.
    J Am Coll Cardiol; 2019 Jul 16; 74(2):179-189. PubMed ID: 31296289
    [Abstract] [Full Text] [Related]

  • 2. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
    Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT.
    J Am Coll Cardiol; 2016 Sep 13; 68(11):1169-1178. PubMed ID: 27609678
    [Abstract] [Full Text] [Related]

  • 3. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP.
    J Am Coll Cardiol; 2017 Mar 21; 69(11):1372-1382. PubMed ID: 28302288
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
    Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, Sritara P, Mercuri MF, Kamphuisen PW, Antman EM, Braunwald E, Giugliano RP.
    J Am Heart Assoc; 2018 Aug 21; 7(16):e008987. PubMed ID: 30369307
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM.
    J Am Heart Assoc; 2016 May 20; 5(5):. PubMed ID: 27207971
    [Abstract] [Full Text] [Related]

  • 6. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
    Corbalán R, Nicolau JC, López-Sendon J, Garcia-Castillo A, Botero R, Sotomora G, Horna M, Ruff CT, Hamershock RA, Grip LT, Antman EM, Braunwald E, Giugliano RP.
    J Am Coll Cardiol; 2018 Sep 25; 72(13):1466-1475. PubMed ID: 30236308
    [Abstract] [Full Text] [Related]

  • 7. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
    Geller BJ, Giugliano RP, Braunwald E, Murphy SA, Hanyok JJ, Jin J, Mercuri M, Antman EM, Ruff CT.
    Am Heart J; 2015 Oct 25; 170(4):669-74. PubMed ID: 26386790
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
    Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E.
    J Am Heart Assoc; 2016 Feb 23; 5(2):. PubMed ID: 26908401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Zelniker TA, Ardissino M, Andreotti F, O'Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA.
    Circulation; 2021 Feb 16; 143(7):673-684. PubMed ID: 33587659
    [Abstract] [Full Text] [Related]

  • 15. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.
    Eur Heart J; 2019 May 14; 40(19):1541-1550. PubMed ID: 30624719
    [Abstract] [Full Text] [Related]

  • 16. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E.
    Circulation; 2016 Jul 05; 134(1):24-36. PubMed ID: 27358434
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
    de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, Grip L, Lanz H, Mercuri MF, Antman EM, Giugliano RP.
    Am Heart J; 2021 May 05; 235():132-139. PubMed ID: 33493453
    [Abstract] [Full Text] [Related]

  • 19. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH, Merino JL, Dan GA, Themistoclakis S, Ellenbogen KA, De Caterina R, Goudev A, Jin J, Melino M, Winters SM, Goette A.
    Am J Cardiol; 2018 Jan 15; 121(2):193-198. PubMed ID: 29169605
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.